Dimensional Fund Advisors LP Sells 228,756 Shares of Health Catalyst, Inc. (NASDAQ:HCAT)

Dimensional Fund Advisors LP lowered its position in Health Catalyst, Inc. (NASDAQ:HCAT) by 14.0% in the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,400,437 shares of the company’s stock after selling 228,756 shares during the period. Dimensional Fund Advisors LP owned 2.37% of Health Catalyst worth $8,948,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in HCAT. Nepsis Inc. grew its stake in shares of Health Catalyst by 8.3% in the 2nd quarter. Nepsis Inc. now owns 1,253,080 shares of the company’s stock worth $8,007,000 after buying an additional 95,686 shares during the last quarter. Kennedy Capital Management LLC purchased a new stake in shares of Health Catalyst in the 1st quarter worth approximately $8,780,000. Acadian Asset Management LLC grew its stake in shares of Health Catalyst by 1.3% in the 2nd quarter. Acadian Asset Management LLC now owns 734,257 shares of the company’s stock worth $4,690,000 after buying an additional 9,697 shares during the last quarter. American Century Companies Inc. grew its stake in shares of Health Catalyst by 1.4% in the 2nd quarter. American Century Companies Inc. now owns 683,464 shares of the company’s stock worth $4,367,000 after buying an additional 9,466 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA grew its stake in shares of Health Catalyst by 17.9% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 331,847 shares of the company’s stock worth $2,121,000 after buying an additional 50,297 shares during the last quarter. Institutional investors own 85.00% of the company’s stock.

Health Catalyst Price Performance

NASDAQ HCAT opened at $7.62 on Tuesday. The business’s fifty day moving average price is $7.43 and its 200-day moving average price is $6.89. The stock has a market capitalization of $449.85 million, a price-to-earnings ratio of -4.12 and a beta of 1.32. Health Catalyst, Inc. has a 1-year low of $5.42 and a 1-year high of $11.41.

Health Catalyst (NASDAQ:HCAT) last announced its earnings results on Wednesday, August 7th. The company reported $0.12 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.04. Health Catalyst had a negative return on equity of 9.38% and a negative net margin of 28.87%. The company had revenue of $75.90 million for the quarter, compared to analysts’ expectations of $74.96 million. During the same period last year, the firm earned ($0.21) EPS. Health Catalyst’s revenue for the quarter was up 3.7% compared to the same quarter last year. Equities research analysts anticipate that Health Catalyst, Inc. will post -0.35 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on HCAT. JPMorgan Chase & Co. upped their price target on Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 4th. Piper Sandler cut their target price on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating on the stock in a research note on Monday, August 26th. Cantor Fitzgerald reiterated an “overweight” rating and set a $16.00 target price on shares of Health Catalyst in a research note on Friday. Stephens cut their target price on Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 8th. Finally, Evercore ISI cut their target price on Health Catalyst from $9.00 to $8.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 9th. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Health Catalyst currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.42.

Insider Buying and Selling

In related news, COO Daniel Lesueur sold 5,209 shares of the firm’s stock in a transaction on Monday, August 5th. The stock was sold at an average price of $6.19, for a total value of $32,243.71. Following the transaction, the chief operating officer now directly owns 150,006 shares of the company’s stock, valued at approximately $928,537.14. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Health Catalyst news, insider Kevin Lee Freeman sold 7,500 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total transaction of $54,150.00. Following the sale, the insider now directly owns 255,881 shares of the company’s stock, valued at $1,847,460.82. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Daniel Lesueur sold 5,209 shares of the firm’s stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $6.19, for a total value of $32,243.71. Following the sale, the chief operating officer now directly owns 150,006 shares in the company, valued at approximately $928,537.14. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 30,153 shares of company stock valued at $216,004. 2.70% of the stock is owned by company insiders.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.